A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy Save

Date Added
February 19th, 2019
PRO Number
Pro00086308
Researcher
Scott Lindhorst

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Brain, Glioblastoma
Summary

This study is for men and women with glioblastoma. The purpose is to see if we can lower the chance of memory loss by adding the drug Ramipirl to the usual chemoradiation treatment.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized, Double-Blind Phase II Trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly diagnosed Glioblastoma (GBM) Save

Date Added
January 8th, 2019
PRO Number
Pro00083430
Researcher
David Cachia

List of Studies

Silhouette
Keywords
Glioblastoma
Summary

The purpose of this study is to find out if adding a chemotherapy drug called pembrolizumab and a vaccine to standard of care treatment (temodar and radiation therapy) for glioblastoma improves survival.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
kellej@musc.edu

Open-Label, Randomized,, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Patients Save

Date Added
January 23rd, 2018
PRO Number
Pro00074342
Researcher
Scott Lindhorst

List of Studies


Profiles_link
Keywords
Glioblastoma
Summary

To assess the safety and efficacy of Trans Sodium Crocetinate (TSC) as first-line treatment for biopsy-only GBM when administered with the standard of care consisting of radiation therapy/temozolomide for 6 weeks, followed by 28 day rest followed by post-radiation temozolomide-only treatment for six 28 day cycles.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
kellej@musc.edu

Change_preferences

-- OR --

Create_login